MasterCard to Delay IPO Until 2nd Quarter San Francisco Chronicle - Feb 16 1:10 PM
MasterCard Inc., the nation's second-largest credit card brand, on Thursday said it will postpone its initial public offering until the second quarter as its chief executive recovers from prostate cancer surgery. The company had been expected to list...Save to My Web
Poverty Trumps Race To Explain Poor Prostate Cancer Outcomes Medical News Today - Feb 17 5:05 AM
Socioeconomic factors predominantly explain racial and ethnic disparities in prostate cancer outcomes, according to a new study. Published in the March 15, 2006 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study found race plays a minor role in prostate cancer survival, and that the most important factors related Save to My Web
Best option for prostate cancer treatment is individual choice Agriculture Online - 58 minutes ago
Allen Lash began with a belief that surgery was his last choice to cure prostate cancer. "When you're diagnosed with prostate cancer, you're dealing with two main issues," he says. "First, your own survival. Second, quality-of-life issues, such as incontinence and sexual function.Save to My Web
FINDINGS Washington Post - Feb 14 11:22 PM
Taking Vitamins E and C or the nutrient beta carotene does not protect against prostate cancer, says the latest study in the continuing, confusing quest to determine when supplements really help health.Save to My Web
Eat soy beans to prevent prostate cancer: Swedish study AFP via Yahoo! News - Feb 14 11:16 AM
Eating food like soy beans and linseeds that naturally contain estrogen-like compounds helps prevent prostate cancer, a researcher in charge of a new Swedish study on the subject said.Save to My Web
MediGene's Prostate Cancer Drug* Launched in France and Other European Countries RedNova - Feb 17 11:16 AM
MARTINSRIED, Germany and SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt, TecDAX) announces that its drug* for the treatment of advanced prostate cancer was launched in France yesterday. The drug* is now available in 11 European countries.Save to My Web